



Integrative Genomic Analysis, Big Data Processing and Programming, and Pharmaco-Informatics in Biomedicine

Guest Editor:

Dr. Bashir Lawal

Department of Pathology,
University of Pittsburgh,
Pittsburgh, PA 15213, USA

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editor

The development of high-throughput omics and deep sequencing technologies has generated a plethora of data in the public and private omics domains. However, laboratory analysis of these data has failed to meet the urgent clinical needs in cancer, diabetes, cardiovascular diseases, and other chronic diseases. Therefore, innovative computational strategies are needed to address urgent clinical problems. The application of multi-disciplinary strategies that include bioinformatics, genetics, molecular and cell biology, and translational studies would accelerate the proper detection of genetic alterations and determine appropriate disease targets based on next-generation sequencing and genome profiling technologies. This Special Issue welcomes multi-disciplinary original research articles and review papers on integrative genomic analysis, computational genomics, big data processing and programming, cancer genetics, immunobiology, immune checkpoint response prediction, drug target identification and validation, network pharmacology, pharmacogenomics, system biology, and protein–ligand interactions, as well as translational research.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)